On April 11th 2022, Genhouse Bio, a biotech company focusing on the development of next-generation small molecule therapeutics, announced that Genhouse Bio has appointed Dr. Haidan Wang as Chief Medical Officer (CMO). Dr. Wang will be fully responsible for the company’s global clinical research and development, significantly enhance Genhouse’s capability in clinical development and accelerate the development of Genhouse’s pipeline products from clinical trials to market.
Prior to joining Genhouse, Dr. Wang was the Vice President of Clinical Development at CSPC Pharmaceutical Group. Before that, he had served in multiple positions in the clinical development function of several well-known clinical CROs, global and domestic pharma or biotech companies such as Novartis, JW Therapeutics, and R&G Pharma. In his twelve-year experience in clinical research and development, Dr. Wang has worked on programs of small molecules, biologics, cell therapies and has successfully led five programs to NDA/BLA submission.
Before entering the pharmaceutical industry, Dr. Wang worked in the oncology department of a tier-one hospital for six years, where he accumulated first-hand clinical experience about the difficulties and pain points in real-world clinical practices. Dr. Wang has also worked at Beijing Food and Drug Administration and has a deep understanding of drug regulation in China.
Dr. Wang holds a doctorate of medicine (M.D.) degree from Air Force Medical University.
“We warmly welcome Dr. Haidan Wang to join us at Genhouse,” said Dr. Kuifeng Wang, the founder and CEO of Genhouse. “Two core assets of Genhouse, KRASG12C inhibitor GH35 and SHP2 inhibitor GH21, are already in clinical development. Our ERK1/2 program GH55 is on the cusp of Phase I clinical study and we’ll soon initiate the IND-enabling studies for multiple assets from Pipeline 2.0. At this critical moment, Dr. Wang’s rich clinical experience, profound medical knowledge and excellent management ability would be indispensable for the rapid development of Genhouse. We believe Dr. Wang will not only enhance Genhouse’s capability in clinical development and translational medicine, but also contribute to our biology-driven and global development strategy.”
“Genhouse Bio focuses on the field of oncology, in particular, it’s at a leading position of targeting RAS-MAPK signaling pathway with the breadth and depth of its Pipeline 1.0,” said Dr. Haidan Wang, the CMO of Genhouse. “Genhouse Bio has been growing rapidly these two years with its core pipelines advancing to clinical stage consecutively. I’m honored to join Genhouse at this critical moment. I look forward to working together with all the teams here to quickly move our pipelines forward into global clinical development, so that the advantages of our assets can be proved in the clinical trials and benefit more patients as soon as possible.”
Genhouse Bio (Suzhou) Ltd. (“Genhouse” or “We”) respects the privacy of visitors (“Users”) to our website www.genhousebio.com (“Site”), so we have developed this website privacy statement (“Privacy Statement”). This Privacy Statement indicates what information we collect about you and how that information is used. We may update the content of the Privacy Statement and suggest reading it regularly when you visit our Site.
Personal Information Collected by Genhouse
When you visit the Site, usually we will not collect any personal information from you. We might track your DNS and analyze the data to obtain understanding on visit trends. However, your identity will always remain anonymous, unless you specifically and knowingly provide it to us. When you provide such information, we will collect your personal information, such as when you contact us through the phone number or email address posted on the Site. But no matter when and how we collect your personal information, we will always provide link to this Privacy Statement. By willingly providing your personal information to us, you make the consent that we could use the information collected according to this Privacy Statement and admit that the information will be transferred from your locale to our office or server.
Information Disclosures and Sharing
Except as provided below, we will not share or sell your Personal Information with third parties unless otherwise stated by this Privacy Statement.
We might share your information according to this Privacy Statement, with Related Party who have consented to follow this Privacy Statement. Your personal information might also be transferred to other Related Party who represents us for purpose stated when we collect those information or other purposes permitted by law, such as Site evaluation, data management or technical support.
We might sell or buy business or assets during our operation. If Genhouse is acquired, merged, reorganized or dissolved or other alike situations happened, personal information might be part of the assets transferred. We may share personal information to respond to duly authorized subpoenas or other lawful information requests of governmental authorities, including to meet national security or law enforcement requirements, to provide Internet security, or where required by law.
We might put a digital tag (more precisely “cookies”) on your hard disk driver for the server to recognize your computer and track usage information. Cookies will not reveal your personal information and you could always stay anonymous to us. The information we collected from Cookies will only be used for internal purpose and improve the service we provided to you through the Site. Users of our Site always have the option of disabling cookies via their browser preferences. If under any circumstances we collected your personal information, we will always inform you with your planned usage, contact and any Third Party that might get this information. All your personal information will maintain secrecy.
Links to Other Websites
If you apply to a job through our Site, you might be directed to other websites operated by Third Party. This Privacy Statement does not extend to any of these websites. Genhouse will not be responsible for any personal information collected by these websites operated by Third Party. Therefore, for any cases that a Third Party collect or use your personal information, Genhouse will not be legally responsible. We advise you to contact those websites directly and get their policies on personal information collection, safety, sharing and disclosure.
If you have any questions about our Privacy Statement, please do not hesitate to contact us at [firstname.lastname@example.org].
Effective and Last Updated: April 15th 2021